Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Despite this setback, Gilead Sciences Inc remains a formidable player in the pharmaceutical industry, with a strong portfolio ...

Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and ...

Gilead Sciences Inc.’s stock rose 2.7% in after-hours trading Wednesday, after the biotech blew past third-quarter earnings ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured ...